afternoon clinic the on clinical quarter, strategy. across believe pipeline candidate our and importantly to the in third well therapeutic strategic in performed joining Thanks, us continue the and our Most call. deliver for development and made we progress for Good thank you update of against our quarter, foothold advances Luke. continued In conference our third results quarter and execute to we initiatives. we microRNA third continued
measures Derisking cost in derisk first II is into and a readouts important have The in designed drug alongside to Development more helped and that to and strategy indication reminder, clinical believe We effective program. Foothold approval. safety Phase human expanded rapid insights a measure Clinical to help model, Progressive design studies and strategy trial designed call we biomarker our a candidate action allow to the guide we drug traditional business a each for of our regulatory pathway, efficiency first trial. Foothold can order of As employed clinical what that clinical build provide potentially the
also believe We to to applicable regulated of functional multiple high cardiovascular is this our unmet and disease areas approach including needs to microRNA addressing medical fibrosis, harmony neurodegeneration disease. oncology, restore
in the in and foundation MRG-XXX. provides of range deep diseases with microRNA disregulation anti-cancer lead is an develop implicated. will I broad biology development drug which strong to candidate candidate to on Our product microRNA treat expertise product our update begin
Lymphoma evaluating MRG-XXX I Mycosis multiple with CTCL. T-Cell currently common are We form or most or a of patients dose Coetaneous The study MF. Fungoides Phase standing and in
sets trial, We to the beyond patients than Based be for to be of EORTC patient’s a continued results we in have to protocol allow longer all pleased able present one of patients treated treated evaluate make we treated continue data well were second on clinical provided for mSWAT patients systemically patient’s our the which the to progress by Lymphoma Severity Meeting new severity modified at skin to administration in trial each we over more opportunity were disease continue the October. have systemic entire the score designed one from to total body. early in the Under ongoing in Phase of I Force maximal the in These amend observed assesses measured trial the Task responses, Assessment patients skin month. Cutaneous improvement disease interim update who which the an as change protocol as dosing to XX on additional from or Weighted call. observations as showed XX the on data included initial patients to as XX% the or of trial patients not month. term we Tool MRG-XXX quarter
for were scores. mSWAT These XX% on who improvement or month therapy. a than of one more to patients nine greater generally maximal treated patients showed Importantly, continued responses XX be for that in appeared durable
MRG-XXX have As of is observation This of durable we for approval an important experienced months reported is five response drug response this patients for indication. important an four the or consideration longer. durability for in as
indications, diffused in direct indications in MRG-XXX. of leukemia/lymphoma, We T-cell in at expansion whether to indication. to-date interim these to of from I and MRG-XXX XXXX. generally expansion were levels with been do tolerated we to together Phase dosing background trial recently oncology appeared additional the have receiving chronic additional B-cell half well included patients patients the for lymphocytic or evaluating currently MRG-XXX early who with correlate Additionally, subjects appears plan so process MRG-XXX these signals with These increase in MRG-XXX of are CTCL in has treating experienced medication of disease large they data showed all Furthermore, Based adult improvement regardless to the microRNA-XXX began three XXX safety leukemia. an we on milligrams. XXXX our release and and expanded dose XX milligrams ranging and In these from each indications efficacy alone. levels, second CTCL indications target in lymphoma, expansion
the a treat controlled to of XXXX will to also we T-cell XXXX. further Phase progress provide on in update patient larger and cutaneous We II throughout trial clinical initiate second MRG-XXX half our lymphoma intend with
in for the profile. between is and in affect causes new deadly the States. United As I the form MF safety can that to need skin. to a XX,XXX tumors be lymphoma, that with common MF a of sometimes MF on mentioned is is treatment condition cases strong most disfiguring painful estimated cutaneous acceptable T-cell XX,XXX people serious many but option disease there
study a American randomized in dose induced to total Phase with for accumulation multiple this Dermatologic to XX trial lead human. Turning in may October. from Keloids In regulate other trial Surgery Meeting excessively. tissue volunteers plan levels the I a evaluated. when fibrotic of escalation able replacements normal MRG-XXX a hard, IIa that deposition Moreover we eye. form A single to in participated wound benign studied evaluate all a predisposition Annual genes tissue MRG-XXX fibroplasias, this placebo in smooth, the growth and not to healing. MRG-XXX double tolerated MRG-XXX based result double reduction of drug dose in clinical in XXXX. candidate, for this indications to fibrotic controlled, lung in microRNA-XX our we include MRG-XXX be at scar results fibrosis first of presented affecting Society evaluating blinded and and generally observed to multiple of was trial an in at in involved well half the appear be for histopathological tissue are grows diseases could We marker blinded keloid subjects formation Future Phase initiate the and scar while cutaneous
maintained, results dose, to preclinical Respiratory our to chemical Exposure new inhalation delivery high suppression Congress via this we its and the the compound integrity was study, after I the potential XXXX. addition of which nose-only lung Society forward now inhalation evaluate on data and will to markers MRG-XXX, to for miRagen the rats. a have of update In data lung The with for presented collaboration could an appeared pulmonary fibrosis MRG-XXX utilized Lovelace and accurate more releasing fibrogenesis. We in the demonstrate candidate to the and Institute. tissue Research additional nebulized safety exposure. under in We assess be effectively of - integrity, International to inhaled look potential preclinical at treatment with that safety European Biomedical particle size, on several Servier. plans system exposure feasibility MRG-XXX, inhalation and product September. fibrosis, of In were administered efficacy treatment provide was with lead of
Phase systemically has scientific half preclinical to of XXXX, both clinical trials delivered new intradermally. initiate plan shown and blood MicroRNA-XX effect inhibitor pharmacodynamic to been reported to an first publications in During we negative of and in a two and microRNA-XXa of creation. multiple reviewed pharmacokinetic peer studies safety, of be MRG-XXX, evaluate the vessel regulator our I
MRG-XXX pharmacokinetics, provide disease I that our of as to show for in in and study biomarkers MRG-XXX trial expanding safety further T-cell clinical and probability MRG-XXX The proof initiating summarize part concept I other believe Jason. development XXXX new appropriate of XXXX. the later ongoing is Leverone, quarter. we XXXX as of controlled proof in clinical of of initiating and for of mechanistic potential critical support foothold miRagen forward clinical Officer of expansion the analyze Servier indication Despite look and and of to early intend these delivering half is to our in of our We the in well We will mechanistic our for Phase clinical clinical dose turn provide is As half in trials, we MRG-XXX by concept may results to to as trial be trial lymphoma in in program. certain MRG-XXX the addition each important Chief made strategy those other have cardiovascular for advancing and conditions in in With third on the in pipeline developing guidance opportunities. we improve quarter to progress flow indication I can concept both over call collaboration oncology believe we proof ranges of trials mission as Phase in with summary, that first in Foothold where microRNA’s studied entire financial human to treatment and In results We Financial the achievement into MRG-XXX help additional designed. need committed targeted believe Phase vascular Jason coetaneous energized of in success first first the is the as mechanistic in clinical advancing believe the fibrosis MRG-XXX the therapy compromised. coetaneous evaluation, candidate been in patients into treatments. innovative the our well have Phase that of Phase II of study. IIa team both I working of development therapeutic
